(INM) InMed Pharmaceuticals Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(INM) InMed Pharmaceuticals Inc. Complete Analysis Pack
InMed Pharmaceuticals: A Quick Look at Its Business Model
Discover how InMed Pharmaceuticals Inc. builds value in the biotech space with a concise, strategic view of its Business Model Canvas. From key partnerships to revenue drivers and cost structure, this resource helps you quickly understand what powers the company. Get the full canvas to unlock deeper insights for analysis, planning, or investment research.
Partnerships
BayMedica Inc. research partnership
InMed Pharmaceuticals Inc. says its BayMedica Inc. research partnership supports formulation and assessment of novel cannabinoid therapeutics for its pipeline. No contract value was disclosed, so the tie-up appears research-focused rather than a major near-term revenue source.
Clinical trial investigators and sites
InMed Pharmaceuticals Inc. relies on clinical trial investigators and sites for INM-755, which is in a second Phase I clinical trial. These partners run the patient enrollment, dosing, and safety monitoring needed to generate human safety data and move the program forward.
Regulatory and ethics review bodies
InMed Pharmaceuticals Inc. must work with regulators and ethics boards in each study country before IND-enabling work can move into humans; in the U.S., an IND is generally allowed to start 30 days after FDA filing if no clinical hold is issued. This gate is critical because every first-in-human study also needs IRB or ethics approval, and trial timelines can slip by weeks if a site review is delayed.
Preclinical and toxicology service providers
InMed Pharmaceuticals Inc. relies on preclinical and toxicology service providers to run IND-enabling pharmacology and safety studies, which are the gatekeepers for dose selection and trial readiness. These specialist labs generate the nonclinical data regulators expect before first-in-human testing, helping reduce late-stage study risk.
- Support IND-enabling safety work
- Define dose and exposure limits
- Screen trial-ready candidates faster
Bioprocess and manufacturing collaborators
InMed Pharmaceuticals Inc. uses bioprocess and manufacturing collaborators to scale IntegraSyn, its biosynthesis platform for pharmaceutical-grade cannabinoids. These partners add process-development know-how and GMP manufacturing support, which matters because scaling to research supply and future commercialization needs controlled, reproducible output.
- Scale-up expertise for IntegraSyn
- GMP manufacturing support
- Supply for research and commercialization
Partnerships lower technical risk while helping InMed move from lab production to larger, regulated batches.
InMed Builds Risk-Sharing Partnerships for R&D, Trials, and Scale-Up
InMed Pharmaceuticals Inc.'s key partnerships are research, trial, and manufacturing links that reduce development risk: BayMedica Inc. for cannabinoid R&D, clinical sites and investigators for INM-755's second Phase I study, regulators and ethics boards for trial approval, and bioprocess partners for IntegraSyn scale-up. No contract value was disclosed.
| Partner | Role | Data |
|---|---|---|
| BayMedica Inc. | R&D support | No disclosed value |
| Clinical sites | Phase I execution | 2nd Phase I |
| Bioprocess partners | Scale-up | GMP supply |
What is included in the product
Detailed Word Document
A concise, real-company Business Model Canvas for InMed Pharmaceuticals Inc. that maps its drug development strategy, customers, channels, and value creation.
Customizable Excel Spreadsheet
Cuts through complexity with a clear, editable one-page view of InMed Pharmaceuticals Inc.’s business model.
Reference Sources
InMed Pharmaceuticals Inc. Reference Sources provide a credible audit trail that supports faster, better-informed decisions.
Activities
Cannabinoid drug discovery
InMed Pharmaceuticals Inc. uses cannabinoid drug discovery to find compounds and formulations for three active areas: dermatology, ocular, and pain programs. This work is the core of its pipeline, turning cannabinoid chemistry into candidate therapies for each indication.
As a small-cap biotech with no approved cannabinoid drugs, InMed’s value comes from advancing these discovery-stage assets toward clinical proof, where hit rates are typically low and each program’s data matters.
INM-755 clinical execution
InMed Pharmaceuticals Inc. is running INM-755 clinical execution for its cannabinol-infused topical cream, now in a second Phase I study for epidermolysis bullosa, a rare disorder affecting about 500,000 people worldwide. Clinical operations focus on safety, tolerability, and skin response, the core readouts that shape dose, design, and next-step development.
IND-enabling studies
InMed Pharmaceuticals Inc. uses IND-enabling studies to run pharmacology and preclinical toxicology work that supports IND filings and trial readiness. These studies are a required gate before larger human trials can start, so they de-risk the jump from lab work to first-in-human testing.
IntegraSyn platform development
IntegraSyn is InMed Pharmaceuticals Inc.’s integrated biosynthesis platform, built to produce pharmaceutical-grade cannabinoids efficiently. Process development is a core internal activity, because InMed controls strain design, biosynthetic optimization, and scale-up in-house to protect quality and reduce third-party dependence.
- Integrated biosynthesis
- Pharma-grade cannabinoids
- Internal process development
- Scale-up control
Pipeline expansion
InMed Pharmaceuticals Inc. is focused on pipeline expansion through INM-088, which is in preclinical studies for glaucoma, and INM-405, which is intended for pain relief. The company is also advancing additional cannabinoid candidates, keeping its R&D work centered on multiple drug programs rather than a single asset.
INM-088: preclinical glaucoma program
INM-405: pain relief candidate
Additional cannabinoid assets in development
InMed Advances Cannabinoid Pipeline and In-House Manufacturing
InMed Pharmaceuticals Inc.’s key activities are cannabinoid discovery, preclinical IND-enabling work, and clinical execution for INM-755 in epidermolysis bullosa, a disorder affecting about 500,000 people worldwide.
It also runs IntegraSyn to make pharma-grade cannabinoids in-house and support scale-up, while advancing INM-088 for glaucoma and INM-405 for pain.
| Activity | Focus |
|---|---|
| Discovery | Cannabinoid candidates |
| Clinical | INM-755 Phase I |
| Platform | IntegraSyn scale-up |
Full Document Unlocks After Purchase
Business Model Canvas
The InMed Pharmaceuticals Inc. Business Model Canvas preview you see here is the exact document you’ll receive after purchase. It’s not a sample or mockup—this is a direct view of the real file, with the same structure and content. Once purchased, you’ll download the full, ready-to-use version exactly as shown.
Resources
INM-755 lead asset
INM-755 is InMed Pharmaceuticals Inc.’s lead asset: a topical cannabinol cream for epidermolysis bullosa, a rare disease affecting about 1 in 20,000 live births. The program is already in Phase I clinical testing, making it the main scientific and value driver in the Company’s pipeline.
INM-088 and INM-405 pipeline
InMed Pharmaceuticals Inc. relies on two key pipeline assets, INM-088 and INM-405, to broaden its development base. INM-088 is in preclinical work for glaucoma, while INM-405 targets pain relief, giving the Company 2 early-stage shots at future value creation.
IntegraSyn biosynthesis platform
IntegraSyn is InMed Pharmaceuticals Inc.’s cannabinoid biosynthesis platform, built to produce pharmaceutical-grade cannabinoids for research and future supply. InMed reported R&D spending of about US$5.7 million in fiscal 2025, and IntegraSyn supports that pipeline by aiming for consistent, scalable output instead of plant-based variability.
Scientific and regulatory expertise
InMed Pharmaceuticals Inc. depends on scientific and regulatory expertise because it is a clinical-stage drug developer, so it needs deep skill in cannabinoid chemistry, toxicology, and clinical trial design to move candidates into human studies. Regulatory know-how is also a core internal asset, since one missed filing or protocol issue can delay development by quarters.
- Clinical-stage drug development
- Cannabinoid chemistry and toxicology
- Clinical design and trial execution
- Regulatory filing and compliance
Intellectual property and data package
InMed Pharmaceuticals Inc.’s key resources are its proprietary drug candidates, manufacturing know-how, and data package. Preclinical, toxicology, and Phase I results reduce development risk and strengthen partner talks and financing, because they turn IP into evidence, not just ideas.
- Proprietary know-how protects value
- Early-stage data supports diligence
- Evidence base improves partnering
InMed’s Core Assets: Pipeline-Driven R&D and IntegraSyn Platform
InMed Pharmaceuticals Inc.’s key resources are its lead cannabinoid programs, IntegraSyn biosynthesis platform, and specialized clinical, toxicology, and regulatory know-how. Fiscal 2025 R&D was about US$5.7 million, showing the Company’s resource base is still centered on pipeline execution rather than revenue generation.
| Resource | 2025 data |
|---|---|
| R&D spend | US$5.7 million |
| Lead asset | INM-755 |
| Platform | IntegraSyn |
Value Propositions
Cannabinoid-based therapeutics
InMed Pharmaceuticals Inc. uses cannabinoid-based therapeutics to target diseases with a different drug class than standard small molecules, and its pipeline spans dermatology, ophthalmology, and neurodegeneration. The company has advanced clinical and preclinical programs, including INM-755 for epidermolysis bullosa and INM-901 for Alzheimer's disease, giving it a multi-asset shot at value creation.
EB topical treatment candidate
INM-755 is InMed Pharmaceuticals Inc.'s topical cream candidate for epidermolysis bullosa, a rare skin disorder affecting about 1 in 50,000 live births and marked by painful, fragile skin with no cure. A cream fits EB care because it targets lesions directly, which can improve local delivery and ease day-to-day use.
Ocular disease pipeline
INM-088 is being developed for glaucoma, a disease affecting over 80 million people worldwide. Ocular disorders are a named focus area for InMed Pharmaceuticals Inc., extending its cannabinoid platform beyond dermatology and into a larger specialty-eye market with clear unmet need.
Pain relief candidate
InMed Pharmaceuticals Inc.’s INM-405 adds a pain-relief angle to the pipeline, widening the target set beyond one use case. Pain is a huge market: CDC data show 24.3% of U.S. adults had chronic pain in 2023, so even one successful indication could reach a very large clinical base.
- INM-405 targets pain relief.
- Pain has broad, recurring demand.
- One asset, more than one indication.
Pharmaceutical-grade cannabinoid supply
IntegraSyn is designed to produce cannabinoids efficiently and at pharmaceutical grade, which matters because InMed Pharmaceuticals Inc. needs tight batch consistency for development and later commercialization. That value proposition supports a cleaner path from lab supply to regulated product supply.
- Efficient cannabinoid production
- Pharmaceutical-grade output
- Consistent supply for development
- Commercialization-ready quality
InMed’s Cannabinoid Pipeline Targets High-Need Diseases
InMed Pharmaceuticals Inc. sells a cannabinoid drug platform aimed at clear unmet needs: rare skin disease, eye disease, pain, and neurodegeneration. Its lead value comes from INM-755 for epidermolysis bullosa, plus INM-088, INM-405, and INM-901, while IntegraSyn supports pharma-grade supply and batch control.
| Value prop | Proof point |
|---|---|
| INM-755 | EB, 1 in 50,000 births |
| INM-088 | Glaucoma, 80M+ people |
| INM-405 | Chronic pain, 24.3% U.S. adults |
Customer Relationships
Clinical trial participant management
InMed Pharmaceuticals Inc. must keep direct contact with enrolled subjects, because Phase I trials often enroll fewer than 100 participants and demand signed informed consent, repeated follow-up, and rapid adverse-event reporting. Safety monitoring stays continuous, with each visit used to check dose tolerance, labs, and any new symptoms.
Investigator and site collaboration
Clinical programs at InMed Pharmaceuticals Inc. rely on tight site-level coordination, because investigators execute the protocol, enroll patients, and collect the data that drive trial quality. These relationships are operationally central, since delayed site start-up or weak follow-up can slow milestones and raise trial costs.
Scientific partnership support
InMed Pharmaceuticals Inc. uses scientific partnership support as a research-led customer link: the BayMedica collaboration shares formulation and assessment work with external scientists, helping validate novel cannabinoid therapies. This kind of co-development lowers clinical and technical risk, and InMed has tied it to a 1-partner external science model focused on early proof of concept.
Investor communication
InMed Pharmaceuticals Inc. is a clinical-stage public company, so investor communication is a core funding tool, not just reporting. Updates on trial progress, pipeline status, and technology milestones help support financing when the company is still pre-revenue and dependent on capital markets.
- Clinical-stage funding depends on investor trust
- Trial updates signal pipeline execution
- Milestones help support future financing
Regulatory interaction
InMed Pharmaceuticals Inc. keeps a formal, compliance-led relationship with regulators because drug development means constant submissions, safety updates, and written responses. InMed’s latest filings show this is not a one-off step: regulatory back-and-forth runs through the whole program, with every study update needing agency review before the next stage.
- Recurring submissions and safety reports
- Formal, compliance-driven contact
- Agency feedback shapes next steps
InMed’s Trial Success Hinges on Patients, Investigators, and Investors
InMed Pharmaceuticals Inc. keeps customer ties highly direct: small Phase I studies usually enroll under 100 subjects, so each patient needs informed consent, repeated visits, and fast safety reporting. Its key external links are investigators, regulators, and investors, all of which shape trial pace, data quality, and funding.
| Relationship | Why it matters |
|---|---|
| Patients | Safety follow-up |
| Investigators | Enrollment and data |
| Investors | Capital support |
Channels
Clinical trial sites
Clinical trial sites are InMed Pharmaceuticals Inc.'s direct path for INM-755, where investigators enroll patients, apply treatment, and capture endpoint data. This is the main execution channel, and INM-755 is being studied in a Phase 2 program on ClinicalTrials.gov.
Scientific conferences and publications
Research-stage biotech companies like InMed Pharmaceuticals Inc. use scientific conferences and peer-reviewed papers to share preclinical and clinical data, build credibility, and reach researchers and potential partners. PubMed indexed more than 38 million citations in 2025, showing how big the scientific channel is for data visibility and deal flow.
Corporate website and investor materials
InMed Pharmaceuticals Inc. uses its corporate website, press releases, and SEC filings to share pipeline and financing updates with investors, analysts, and other stakeholders. These channels are the main public path for a Nasdaq-listed company to report results and clinical progress on a quarterly and annual basis.
Partner and collaborator networks
InMed Pharmaceuticals Inc. uses partner and collaborator networks to extend BayMedica’s scientific work into distribution, with external links helping fill gaps in formulation and assessment expertise. This setup can also lower development friction and support future licensing talks if the data package is strong.
- BayMedica supports partner-based distribution
- External experts add formulation depth
- Assessment support can speed licensing talks
Regulatory submission pathways
InMed Pharmaceuticals Inc. must clear formal regulatory gates before each program move: IND-enabling work feeds an FDA IND, and the IND becomes active after the 30-day review window if no clinical hold is issued. That makes submission timing a core channel for clinical advancement, not just a filing step.
- FDA IND review window: 30 days
- Each transition needs fresh submission data
- Clinical holds can block the next phase
How InMed Reaches Patients, Investors, and FDA Gatekeepers
InMed Pharmaceuticals Inc. mainly reaches patients through clinical trial sites for INM-755, while investors and partners get updates through its website, press releases, SEC filings, conferences, and peer-reviewed papers. FDA IND timing is also a key channel gate: the review window is 30 days, and each step needs new data.
| Channel | Role | Key fact |
|---|---|---|
| Clinical sites | Patient enrollment and data capture | INM-755 is in Phase 2 |
| Public disclosures | Investor communication | Quarterly and annual filings |
| FDA IND | Clinical gate | 30-day review window |
Customer Segments
EB patients and caregivers
INM-755 targets epidermolysis bullosa, a rare disease affecting about 1 in 20,000 live births worldwide; patients live with severe skin fragility, blistering, and lifelong wound care. Caregivers often help choose treatment, manage daily dressings, and support the high care burden, making them part of the buying unit.
Dermatologists and rare disease specialists
Dermatologists and rare disease specialists are key prescribers and trial investigators for InMed Pharmaceuticals Inc., especially in epidermolysis bullosa, a rare skin disorder that affects about 1 in 50,000 live births and roughly 500,000 people worldwide. They help recruit patients, manage complex skin care, and can speed future adoption if clinical data show benefit.
Ophthalmologists and glaucoma specialists
Ophthalmologists and glaucoma specialists are the clinical audience for InMed Pharmaceuticals Inc.'s INM-088 program, which is being studied in glaucoma. These eye-care specialists are the likely future prescribers in a market that affects about 76 million people worldwide today and is projected to reach 111.8 million by 2040.
Pain management clinicians
Pain management clinicians are the core clinical gatekeepers for INM-405, which is being developed for pain relief, so pain specialists, anesthesiologists, and related physicians are the first users to influence adoption. Chronic pain affects about 51.6 million U.S. adults, so if INM-405 advances clinically, this segment can drive prescribing, trial referral, and payer uptake.
- Targets pain specialists and related physicians
- Clinical adoption depends on trial results
- Large need: 51.6 million U.S. adults
Biopharma partners and investors
InMed Pharmaceuticals Inc. is clinical-stage and pre-commercial, so biopharma partners are key for funding, co-development, and late-stage risk sharing. Investors also matter because they supply the capital that keeps R&D and trials moving before any product sales exist.
- Partners can co-fund assets
- Investors finance R&D and trials
- Pre-commercial, no product revenue
InMed Targets Rare Disease, Eye Care, and Pain Markets
InMed Pharmaceuticals Inc. serves a rare-disease and specialty-care base: EB patients and caregivers, dermatologists, ophthalmologists, glaucoma specialists, and pain clinicians tied to its pipeline. The company is still pre-commercial, so biopharma partners and investors remain core customer segments funding R&D and trials.
| Segment | Key data |
|---|---|
| EB | ~1 in 20,000 births |
| Glaucoma | 76M global; 111.8M by 2040 |
| Pain | 51.6M U.S. adults |
Cost Structure
Clinical trial expenses
Clinical trial expenses are a core cash use for InMed Pharmaceuticals Inc.: Phase I studies need sites, patients, monitoring, and data management, and INM-755 is already in its second Phase I trial. For a small biotech, that means repeated upfront spend before any product revenue, so this line item stays one of the main drivers of R&D burn.
Preclinical and toxicology spend
InMed Pharmaceuticals Inc. still has IND-enabling pharmacology and toxicology work running, so this cost line stays tied to R&D and uses specialized, regulated labs under GLP rules. These studies are a gatekeeper before later-stage trials, and for a small biotech they can absorb a large share of cash burn even before human dosing starts.
Research and process development
InMed Pharmaceuticals Inc. keeps research and process development as a fixed cost driver in FY2025, because IntegraSyn and formulation work need scientists, lab equipment, cannabinoid production, process optimization, and analytical testing. Spending stays continuous, since each new batch and assay adds cash burn through the year.
Regulatory and quality costs
Regulatory and quality costs are a core drag on InMed Pharmaceuticals Inc. because every drug program needs filings, documentation, audits, and compliance systems, while pharmaceutical-grade cannabinoids must meet GMP standards. These costs typically climb as programs move from preclinical work into clinical and manufacturing stages.
- Rises with each development stage.
- Drives filing, QA, and compliance spend.
- Needed for GMP-grade cannabinoid output.
Corporate overhead and intellectual property
InMed Pharmaceuticals Inc. carries clinical-stage biotech overhead tied to being a public Company Name: management, legal, audit, and stock-exchange reporting. These head office costs also fund patent filing and defense, which protect the pipeline while the company advances cannabinoid programs through trials.
For this cost bucket, the key watch items are G&A, IP spend, and cash burn, because they rise before revenue does.
- Public-company reporting costs
- Management and legal spend
- Patent filing and defense
- Head office supports trials
InMed’s FY2025 Burn Is Driven by Heavy R&D and Clinical Trial Spend
InMed Pharmaceuticals Inc. cost structure in FY2025 is R&D-heavy: Phase I trials, IND-enabling studies, process development, and GMP/GLP compliance drive most spend, while public-company G&A, legal, and patent costs add steady overhead. The key pressure point is cash burn before product revenue.
| FY2025 cost driver | Impact |
|---|---|
| Clinical trials | High |
| IND-enabling work | High |
| R&D/process dev | High |
| G&A/IP | Medium |
Revenue Streams
Equity financing
InMed Pharmaceuticals Inc. relies on equity financing as a core funding stream because clinical-stage biotech firms usually have little or no product revenue before approval. In 2025, this type of capital kept R and D moving by funding trials, IP, and lab work without adding debt.
Collaboration income
InMed Pharmaceuticals Inc. uses collaboration income to bring in contracted funding from research partners, and BayMedica-style sponsored work can help pay for development. In FY2025, this kind of partner cash is especially valuable because it can offset R&D spending before product sales scale.
Licensing and option payments
In biotech, upfront fees and option payments often land in the $1 million to $5 million range, with bigger deals adding milestones later. For InMed Pharmaceuticals Inc., licensing pipeline assets to larger pharma partners can bring non-dilutive cash, so it funds R&D without issuing more shares.
Milestone payments
InMed Pharmaceuticals Inc. can use milestone payments from development deals to bring in cash as clinical and regulatory goals are hit, such as trial starts, dose readouts, or approvals. That ties revenue to de-risking, so each payment reflects a lower-risk asset.
For a small biotech, this is a cleaner fit than fixed sales because it rewards progress, not volume.
- Clinical milestones unlock cash
- Regulatory approvals trigger payments
- Revenue rises as risk falls
Future royalties and product sales
InMed Pharmaceuticals Inc. is still clinical-stage, so revenue from future product sales only starts if a candidate wins approval and reaches market. Royalties can also come from licensed assets, but these are future streams, not current recurring revenue.
- Sales start after approval.
- Royalties come from licenses.
- FY2025 was still pre-commercial.
InMed’s Cash Story: Equity Today, Non-Dilutive Upside Tomorrow
InMed Pharmaceuticals Inc.'s revenue mix in FY2025 was still pre-commercial: no meaningful product sales, with cash coming mainly from equity financing, partner-funded research, and licensing-style deals. This makes non-dilutive cash vital, since milestone and royalty income only scale after clinical and regulatory wins.
| Stream | FY2025 role | Cash type |
|---|---|---|
| Equity | Main funding | Dilutive |
| Collaborations | R and D support | Non-dilutive |
| Licensing | Future upside | Milestone/royalty |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.